Two compounds. Two completely different mechanisms. One growing research conversation.
Last reviewed: August 2026 | Written by the True Ability Labs Research Team | All claims cited to peer-reviewed sources below.
Ozempic is the most searched metabolic drug in the UK right now. 5-Amino-1MQ is the most studied oral NNMT inhibitor available to UK researchers. They are not the same thing — they do not work the same way, they do not target the same pathway, and they are not interchangeable.
But researchers are comparing them. Here is why — and what the science actually says.
What Is Ozempic (Semaglutide)?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist (glucagon-like peptide-1) developed by Novo Nordisk and approved by the MHRA for the treatment of type 2 diabetes and, under the brand name Wegovy, for chronic weight management in adults [1].
Semaglutide works by mimicking the GLP-1 hormone, which is naturally released after eating. It acts on GLP-1 receptors in the pancreas to stimulate insulin secretion, suppresses glucagon release, and — critically for its weight management application — acts on GLP-1 receptors in the brain to reduce appetite and slow gastric emptying [1].
In the STEP 1 clinical trial (2021), once-weekly semaglutide 2.4mg produced a mean weight reduction of 14.9% over 68 weeks in adults with obesity — a landmark result that drove the current wave of clinical and public interest [2].
Administration: Semaglutide is administered via weekly subcutaneous injection (Ozempic/Wegovy) or daily oral tablet (Rybelsus). It is a prescription-only medicine in the UK.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective, cell-permeable small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — an enzyme expressed primarily in adipose tissue that regulates NAD+ biosynthesis and the cellular methylation cycle [3].
It does not act on GLP-1 receptors. It does not suppress appetite via central nervous system pathways. It works upstream — at the enzymatic level — by inhibiting NNMT and thereby restoring NAD+ and SAM (S-adenosylmethionine) availability in metabolically active tissue [4].
In the foundational Neelakantan et al. (2018) study, oral administration of 5-Amino-1MQ in high-fat diet mice was associated with reduced weight gain and improved metabolic markers — without appetite suppression as the primary mechanism [3].
Administration: Oral capsule. Available as a research compound / food supplement in the UK. Not a prescription medicine.
For a full explainer on the NNMT mechanism, see: 5-Amino-1MQ: The NNMT Inhibitor Redefining Metabolic Research in 2026.
The Mechanism Comparison
| Semaglutide (Ozempic) | 5-Amino-1MQ | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | NNMT enzyme inhibitor |
| Primary target | GLP-1 receptors (pancreas, brain) | NNMT enzyme (adipose tissue, liver) |
| Appetite suppression | Yes — central mechanism [1] | Not a primary mechanism [3] |
| NAD+ pathway | No direct effect | Restores NAD+ via NNMT inhibition [4] |
| Administration | Weekly injection or daily oral tablet (Rx) | Daily oral capsule (research compound) |
| Regulatory status (UK) | Prescription-only medicine (MHRA approved) | Food supplement / research compound |
| Human clinical trial data | Extensive (STEP trials, SUSTAIN trials) | Preclinical only (no published human RCTs) |
Why Are Researchers Comparing Them?
The comparison is not about substitution — it is about mechanism diversity in metabolic research. Both compounds are being studied in the context of metabolic dysfunction, but they address it through entirely different biological pathways:
- Semaglutide reduces caloric intake via appetite suppression and slows gastric emptying — a hormonal, top-down approach [1]
- 5-Amino-1MQ targets the enzymatic environment within fat cells — a cellular, bottom-up approach [3]
Researchers interested in the NAD+/methylation axis — and its relationship to metabolic health independent of caloric restriction — are specifically interested in NNMT inhibition as a complementary area of investigation to GLP-1 research.
What 5-Amino-1MQ Is Not
To be unambiguous:
- 5-Amino-1MQ is not an Ozempic alternative for weight loss treatment
- It is not approved by the MHRA or FDA for any therapeutic use
- It does not replicate the GLP-1 mechanism
- It is a research compound supplied for investigational purposes only
Anyone seeking semaglutide for medical purposes should speak to a qualified healthcare professional and obtain it via prescription through legitimate UK channels.
For UK Researchers
If your research interest is in the NNMT/NAD+ axis — rather than GLP-1 receptor pharmacology — 5-Amino-1MQ is the most studied oral NNMT inhibitor currently available in the UK, accurately dosed at 50mg per capsule, dispatched same day.
Before sourcing, read our NNMT Inhibitor Buyer's Guide to understand what separates research-grade from grey-market supply. For dosing context, see our 5-Amino-1MQ Dosage Guide.
Have more questions? Visit our FAQ page.
References
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism. 2021;46:101102. PubMed: 34170647
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002. PubMed: 33567185
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. PubMed: 30257040
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. PubMed: 23604011
Food supplement. Not a medicine. Not intended to diagnose, treat, cure, or prevent any disease. For research purposes only. Always consult a qualified healthcare professional before use. Semaglutide (Ozempic/Wegovy) is a prescription-only medicine — obtain it only via a licensed UK prescriber.
